GlassScriptPhysician profile
James W Edmondson
NPI 1831154863
$10,476.00
in general payments reported to CMS, 2019-2025
50 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $550 · 2021: $1,358 · 2022: $980 · 2023: $1,988 · 2024: $2,422 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,561.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,691.81 | 2019-2025 | Repatha, Evenity, Tepezza |
| Novo Nordisk INC | $1,289.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $694.67 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $639.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $479.47 | 2019-2024 | |
| Radius Health, INC. | $418.13 | 2019-2025 | Tymlos |
| Abbvie INC. | $401.42 | 2019-2025 | Synthroid |
| Novartis Pharmaceuticals Corporation | $387.67 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $350.63 | 2020-2025 | Gvoke Hypopen |
| Abbott Laboratories | $350.07 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $333.34 | 2022-2025 | |
| Dexcom, INC. | $276.97 | 2021-2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $254.76 | 2019-2025 | Unithroid |
| Esperion Therapeutics, INC. | $248.68 | 2021-2025 | Nexletol |
| Insulet Corporation | $229.43 | 2023-2025 | Omnipod |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.16 | 2021-2025 | Jardiance |
| Antares Pharma, INC. | $182.30 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Corcept Therapeutics | $180.77 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $180.31 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $165.39 | 2022-2025 | Strensiq |
| Mannkind Corporation | $156.61 | 2021-2023 | Afrezza |
| Janssen Pharmaceuticals, INC | $148.91 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $144.54 | 2019-2024 | Aveed, Xiaflex |
| Horizon Therapeutics Plc | $123.03 | 2019-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $68.65 | 2021-2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $62.73 | 2020 | |
| Neurocrine Biosciences, INC. | $56.17 | 2025 | |
| Amarin Pharma, INC. | $55.85 | 2020-2021 | |
| Halozyme INC | $53.84 | 2023 | |
| Medtronic, INC. | $49.48 | 2023-2025 | Minimed 780g |
| Endo USA, INC. | $41.40 | 2024-2025 | Aveed, Xiaflex |
| Beta Bionics, INC. | $40.49 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Chiesi USA, INC. | $39.86 | 2024 | Mycapssa, Myalept |
| Lifescan, INC. | $39.85 | 2020-2022 | |
| Cequr Corporation | $37.71 | 2023-2024 | Cequr Simplicity |
| Amryt Pharma Holdings LTD | $37.31 | 2022-2023 | Mycapssa |
| Sequel Med Tech, LLC | $36.50 | 2025 | Twiist |
| Takeda Pharmaceuticals U.S.A., INC. | $36.10 | 2020-2021 | |
| Medtronic Minimed, INC. | $35.57 | 2019 | |
| Zealand Pharma US, INC. | $33.37 | 2021 | |
| Pfizer INC. | $32.86 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $32.66 | 2021-2024 | Crysvita |
| Shire North American Group INC | $31.91 | 2019 | |
| Merck Sharp & Dohme LLC | $24.60 | 2021 | |
| Senseonics, Incorporated | $21.00 | 2019 | |
| Averitas Pharma INC. | $20.06 | 2023 | Qutenza |
| Rgh Enterprises LLC | $19.53 | 2025 | |
| Soleno Therapeutics, INC. | $19.49 | 2025 | Vykat Xr |
| Ascendis Pharma Endocrinology INC | $15.49 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $14.29 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Edmondson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.